Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated NK cells in solid tumors
NCT03634501Phase 2Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2018
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in lung cancer, breast cancer, colon cancer and 2 more, sponsored by Xuanwu Hospital. Primary endpoint: Incidence of toxicity induced by NK infusion at 6 months. Status: unknown.
02
Conditions
lung cancerbreast cancercolon cancerpancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT03634501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634501.